Neuroleptic malignant-like syndrome due to donepezil and maprotiline.
Ohkoshi
Norio
N
Department of Neurology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan. ohkoshin@ md.tsukuba.ac.jp
Satoh
Daisuke
D
Nishi
Masaaki
M
Shoji
Shin'ichi
S
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D000077265:Donepezil; D004357:Drug Synergism; D006801:Humans; D007189:Indans / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008376:Maprotiline / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D010880:Piperidines / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
D018687:Antidepressive Agents, Second-Generation; D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D008376:Maprotiline; D000077265:Donepezil